Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, is a progressive lysosomal storage disorder caused by pathogenic variants in the IDS gene. It is inherited in an X-linked pattern and primarily affects males. The deficiency of iduronate-2-sulfatase prevents the proper degradation of heparan sulfate and dermatan sulfate, leading to the accumulation of glycosaminoglycans (GAGs) and multisystem damage, with possible neurological involvement.
Mucopolysaccharidosis type 2
The IDS gene provides the instructions for producing the enzyme iduronate-2-sulfatase (I2S), a lysosomal sulfatase essential for the degradation of glycosaminoglycans. This enzyme participates in the catabolism of heparan sulfate and dermatan sulfate, removing sulfate groups necessary for these molecules to be degraded and recycled within lysosomes.
When pathogenic variants exist in IDS, the activity of iduronate-2-sulfatase is markedly reduced or absent. As a consequence, GAGs progressively accumulate in cells and tissues, causing involvement of the skeleton, joints, heart, respiratory tract, liver, spleen, and, in the most severe forms, the central nervous system. MPS II is considered a clinical spectrum that includes neuronopathic forms, with progressive cognitive deterioration, and non-neuronopathic or attenuated forms, with predominant systemic involvement. X-linked inheritance explains why most patients are hemizygous males; carrier females are usually asymptomatic, although they can rarely present with manifestations. The incidence is estimated to be around 1 in 100,000 to 170,000 live-born males.
Symptoms
Symptoms usually appear between 18 months and 4 years of age, although the age of onset and progression are variable. Common findings include coarse facial features, macrocephaly, macroglossia, hepatosplenomegaly, umbilical or inguinal hernias, recurrent respiratory infections and otitis, hearing loss, joint stiffness, multiple dysostosis, and valvular heart disease. In neuronopathic forms, developmental delay, behavioral disturbances, and progressive cognitive deterioration are observed. Urinalysis typically shows elevated GAGs in urine, especially dermatan sulfate and heparan sulfate.
Disease management
The management of MPS II is multidisciplinary and must be adapted to each patient's phenotype. Intravenous enzyme replacement therapy with idursulfase can reduce GAG accumulation and improve somatic manifestations, although it crosses the blood-brain barrier to a limited extent and does not adequately control neurological involvement. In some contexts, enzyme therapies designed to reach the central nervous system exist, indicated only in selected patients and according to regulatory availability. Monitoring should include cardiological, respiratory, auditory, orthopedic, neurological, and developmental assessment, in addition to physical therapy, educational support, infection management, and family genetic counseling.
Genes analyzed
Bibliography
Scarpa M, Lampe C. Mucopolysaccharidosis Type II. 2007 Nov 6 [updated 2025 Jan 16]. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025.
Zanetti A, D'Avanzo F, Tomanin R. Molecular basis of mucopolysaccharidosis type II (Hunter syndrome): first review and classification of published IDS gene variants. Hum Genomics. 2024 Dec 2;18(1):134.
